Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic Syndromes

Learn current and emerging best practices in the treatment of your patients with myelodysplastic syndromes (MDS) with this case-based, interactive, expert-led meeting series.

Agenda

  • MDS Overview
  • Novel Therapeutic Approaches for the Treatment of Lower-Risk MDS
  • Managing Anemia in Very Low–, Low-, or Intermediate-Risk MDS
  • Treatment Approaches in Patients With Higher-Risk MDS
  • Clinical Strategies for Patients With Relapsed/Refractory MDS
  • Closing Remarks and Question-And-Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Program Director
Rami Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Professor
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Goal Statement
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current and emerging best practices in the treatment of myelodysplastic syndromes.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with myelodysplastic syndromes.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with MDS based on individual patient and disease characteristics and validated risk stratification tools
  • Discuss unique clinical challenges associated with the care of elderly patients with MDS
  • Integrate the available clinical data, treatment guidelines, and expert recommendations when selecting treatment in the settings of low-, intermediate-, and high-risk groups, as well as MDS with adverse or targetable genetic features
  • Integrate novel management options for managing MDS-related anemia, neutropenia and thrombocytopenia
  • Recognize and manage adverse events associated with current and recently approved systemic therapies in MDS
  • Evaluate the available clinical data on promising investigational agents and emerging combination therapies for managing high-risk MDS

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN Live Meetings: JA4008176-0000-21-234-L01-P

UAN Virtual: JA4008176-0000-21-233-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.